Cognito Unveils New Brand to Reflect Enhanced Capabilities and Changing Markets
Cognito, the independent global communications agency, has today announced the launch of its new brand identity. Five years on from the last refresh, the new look and positioning reflects the agency’s growth and expansion across service lines, sectors and geographies to meet the needs of its global client roster. The agency’s client base comprises over 100 firms in finance, technology and professional services from the largest and best-known brands in the industry to dynamic start and scale ups.
The new brand design reflects the agency’s unique approach to solving business challenges, commitment to innovation and bringing new thinking and ideas to clients and the industry. It’s also an expression of the different perspectives and experiences Cognito holds across its global team; speaking over 20 languages, from over 15 countries from offices in the US, EMEA, and APAC.
Cognito has launched a dedicated Sustainability Practice to help clients with the Climate Transition. Earlier this year, Cognito also opened an office in Sydney to boost its reach across APAC alongside its core regional hubs in Hong Kong and Singapore.
Tom Coombes, Cognito’s Founder and CEO, comments: “The new Cognito brand reflects where we are as an agency, the services we offer, the geographies we work in and the strength of expertise we have. We know clients are facing increasingly complicated challenges. We believe that we can now offer unparalleled services across the communication and marketing mix. All our services and advice are designed for clients who work in complex and competitive markets. The new brand is a reflection of our appetite to help our clients thrive in these dynamic sectors and our ambition to be the agency of choice globally.”
Cognito is an independent global communications agency driving the conversations that matter for our clients in financial markets, technology and the climate transition. We champion them as they lead the way to sustainable development and a more connected world.
We advise organizations, from established leaders to startup challengers, on how to manage reputation, handle threats, and build value in complex and competitive markets. With creative content and an understanding of channel complexity, we protect and grow our clients’ businesses through purpose-driven communications and stakeholder engagement.
Our team of consultants around the world bring together 20 languages from 15 countries, with big agency and in-house expertise working across corporate communications, PR, digital marketing and social. You can find us on the ground in key financial markets - London, Amsterdam, New York, Los Angeles, Singapore, Hong Kong and Sydney - infusing local knowledge and culture in our 7 offices with multi- national resources, the same standards of excellence and a truly global perspective.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients with Heavily Pretreated HR Positive, HER2 Low or Negative Metastatic Breast Cancer9.12.2022 00:00:00 CET | Press release
Initial results from the TROPION-PanTumor01 phase 1 trial of datopotamab deruxtecan (Dato-DXd) showed encouraging and durable efficacy in patients with heavily pretreated hormone receptor (HR) positive, HER2 low (immunohistochemistry [IHC] 1+ or IHC 2+/in-situ hybridization [ISH]-) or HER2 negative (IHC 0) unresectable or metastatic breast cancer. Safety data were consistent with previous trials of datopotamab deruxtecan. Results were presented today as a Spotlight Poster Discussion (Abstract #PD13-08) at the 2022 San Antonio Breast Cancer Symposium (#SABCS22). Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN). Approximately 70% of breast cancer tumors are considered HR positive and HER2 low or negative.1 For patients with HR positive, HER2 low or negative metastatic breast cancer that progress on or are not suitable candidates for endocrine the
TreviPay Acquires Apruve8.12.2022 23:45:00 CET | Press release
TreviPay, a leader in global B2B payments and invoicing solutions, today announced the signing of a definitive agreement to acquire payment platform Apruve. Apruve offers a robust suite of payment solutions for global enterprises that will complement and expand on TreviPay’s existing order-to-cash technology offerings, merchant invoicing solutions, and the geographical reach of TreviPay’s existing B2B networks. TreviPay has experienced unprecedented demand from global enterprise buyers and sellers resulting in 30% organic growth in 2022, and this acquisition furthers TreviPay's plans to expand its order-to-cash technology offerings and B2B payment network. This acquisition builds on TreviPay’s recent purchase of Baton Financial Services. “TreviPay provides payment and invoicing solutions for a number of leading manufacturers and OEMs; the acquisition of Apruve will accelerate our advancement in the technology manufacturing vertical and expand our geographic reach into key Asian markets
Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy8.12.2022 22:05:00 CET | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the CONTACT-01 study did not meet its primary endpoint of overall survival (OS) at the final analysis. CONTACT-01 is a phase III clinical trial evaluating Cabometyx® (cabozantinib) in combination with atezolizumab (Tecentriq®) versus docetaxel in patients with unmutated metastatic non-small cell lung cancer (NSCLC) who experienced disease progression on or after treatment with an immune checkpoint inhibitor and platinum-containing chemotherapy. Howard Mayer, M.D., Executive Vice President, Head of Research and Development at Ipsen, said: “The results from the CONTACT-01 clinical trial have shown the challenge of treating NSCLC patients after prior lines of treatment have failed. While the findings of the study have not met the primary endpoint in this setting, we remain confident in the clinical efficacy of cabozantinib alone and in combination with another treatment in existing indications in difficult-to-treat tu
Verisign Reports Internet Has 349.9 Million Domain Name Registrations at the End of the Third Quarter of 20228.12.2022 21:57:00 CET | Press release
VeriSign, Inc. (NASDAQ: VRSN), a global provider of domain name registry services and internet infrastructure, today announced that the third quarter of 2022 closed with 349.9 million domain name registrations across all top-level domains, a decrease of 1.6 million domain name registrations, or 0.4%, compared to the second quarter of 2022.1,2 Domain name registrations have increased by 11.5 million, or 3.4%, year over year.1,2 The .com and .net TLDs had a combined total of 174.2 million domain name registrations in the domain name base3 at the end of the third quarter of 2022, a decrease of 0.2 million domain name registrations, or 0.1%, compared to the second quarter of 2022. The .com and .net TLDs had a combined increase of 2.1 million domain name registrations, or 1.2%, year over year. As of Sept. 30, 2022, the .com domain name base totaled 160.9 million domain name registrations, and the .net domain name base totaled 13.2 million domain name registrations. New .com and .net domain
Citi Global Wealth Investments Releases Outlook 2023: Roadmap to Recovery: Portfolios to Anticipate Opportunities8.12.2022 20:07:00 CET | Press release
Citi Global Wealth Investments (CGWI) today released its Wealth Outlook 2023 (Outlook) report, titled Roadmap to Recovery: Portfolios to Anticipate Opportunities. Published twice yearly, Outlook provides in-depth insights into the global economy and financial markets for the year ahead and beyond. The latest edition’s title reflects the investing journey that CGWI envisions and the steps that investors should consider diversifying their portfolios. In 2023, CGWI predicts the weakest annual global economic growth in forty years outside of the Global Financial Crisis and the COVID shutdowns. The year ahead is likely to see: A shallow US recession and worse in some other places such as the Eurozone A recovery in Chinese growth, by contrast, as pandemic restrictions are relaxed US inflation continuing to ease, ending 2023 at around 3.5% The US Federal Reserve to start cutting interest rates by the second half of the year A 10% drop in global earnings per share Just as 2022’s global market